在沃尔特里德陆军医疗中心，对来自战伤患者的鲍曼不动杆菌-醋酸钙不动杆菌的氨基糖苷类抗生素阿贝卡星的体外活性研究。
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
机构信息
Infectious Disease Service, Walter Reed Army Medical Center, 6900 Georgia Ave., Washington, DC 20307, USA.
出版信息
Antimicrob Agents Chemother. 2010 Jul;54(7):3015-7. doi: 10.1128/AAC.01173-09. Epub 2010 Apr 19.
Abstract
We determined the in vitro MIC of arbekacin against 200 Acinetobacter isolates recovered from wounded soldiers. The median MIC was 2 microg/ml (range, 0.5 to > 64 microg/ml). A total of 97.5% of the isolates had arbekacin MICs of < 8 microg/ml and 86.5% had MICs of < or = 4 microg/ml. There was no association between the arbekacin MIC and susceptibility to 16 other antibiotics or the specimen source (P = 0.7239). Synergy testing suggested an enhanced effect of arbekacin-carbapenem combinations.
摘要
我们测定了阿贝卡星对 200 株从受伤士兵中分离的不动杆菌的体外 MIC。中位 MIC 为 2μg/ml（范围 0.5 至>64μg/ml）。共有 97.5%的分离株阿贝卡星 MIC 值<8μg/ml，86.5%的 MIC 值<或=4μg/ml。阿贝卡星 MIC 值与对 16 种其他抗生素的敏感性或标本来源之间无相关性（P=0.7239）。协同试验提示阿贝卡星-碳青霉烯类联合用药有增效作用。
相似文献
1
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Antimicrob Agents Chemother. 2010 Jul;54(7):3015-7. doi: 10.1128/AAC.01173-09. Epub 2010 Apr 19.
2
Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2015 Apr;59(4):2286-98. doi: 10.1128/AAC.04379-14. Epub 2015 Feb 2.
3
In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.
J Antimicrob Chemother. 2019 Apr 1;74(4):944-952. doi: 10.1093/jac/dky546.
4
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104.
5
In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals.
Braz J Infect Dis. 2001 Jun;5(3):130-5. doi: 10.1590/s1413-86702001000300005. Epub 2003 Feb 19.
6
Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.
Antimicrob Agents Chemother. 2015;59(6):3263-70. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23.
7
Emergence of Aminoglycoside Resistance Due to armA methylase in Multi-drug Resistant Acinetobacter Baumannii Isolates in a University Hospital in Nepal.
J Nepal Health Res Counc. 2016 May;14(33):72-76.
8
In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S188-91. doi: 10.1016/S0924-8579(08)70026-8.
9
In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan.
J Microbiol Immunol Infect. 2016 Dec;49(6):918-923. doi: 10.1016/j.jmii.2015.07.010. Epub 2015 Aug 14.
10
In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
Diagn Microbiol Infect Dis. 2016 Oct;86(2):184-9. doi: 10.1016/j.diagmicrobio.2016.07.017. Epub 2016 Jul 19.
引用本文的文献
1
Clinical Usefulness of Arbekacin.
Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Epub 2016 Mar 31.
2
Mutational and acquired carbapenem resistance mechanisms in multidrug resistant Pseudomonas aeruginosa clinical isolates from Recife, Brazil.
Mem Inst Oswaldo Cruz. 2015 Dec;110(8):1003-9. doi: 10.1590/0074-02760150233. Epub 2015 Dec 15.
3
Detecting 16S rRNA Methyltransferases in Enterobacteriaceae by Use of Arbekacin.
J Clin Microbiol. 2016 Jan;54(1):208-11. doi: 10.1128/JCM.02642-15. Epub 2015 Nov 4.
4
Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.
Antimicrob Agents Chemother. 2015;59(6):3263-70. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23.
5
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.
Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014.
6
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
PLoS One. 2014 Jul 28;9(7):e103253. doi: 10.1371/journal.pone.0103253. eCollection 2014.
7
Detection of New Delhi metallo-β-lactamase (encoded by blaNDM-1) in Acinetobacter schindleri during routine surveillance.
J Clin Microbiol. 2013 Jun;51(6):1942-4. doi: 10.1128/JCM.00281-13. Epub 2013 Apr 3.
本文引用的文献
1
Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
Clin Infect Dis. 2009 Jun 15;48(12):1724-8. doi: 10.1086/599225.
2
Emergence of multidrug resistance in bacteria and impact on antibiotic expenditure at a major army medical center caring for soldiers wounded in Iraq and Afghanistan.
Infect Control Hosp Epidemiol. 2008 Jul;29(7):661-3. doi: 10.1086/588702.
3
Combat wounds in operation Iraqi Freedom and operation Enduring Freedom.
J Trauma. 2008 Feb;64(2):295-9. doi: 10.1097/TA.0b013e318163b875.
4
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.
Clin Infect Dis. 2007 Jan 1;44(1):79-86. doi: 10.1086/510079. Epub 2006 Nov 27.
5
Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2006 Nov;50(11):3763-9. doi: 10.1128/AAC.00480-05.
6
Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.
J Korean Med Sci. 2006 Apr;21(2):188-92. doi: 10.3346/jkms.2006.21.2.188.
7
In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals.
Braz J Infect Dis. 2001 Jun;5(3):130-5. doi: 10.1590/s1413-86702001000300005. Epub 2003 Feb 19.
8
Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.
Antimicrob Agents Chemother. 2000 Sep;44(9):2545-6. doi: 10.1128/AAC.44.9.2545-2546.2000.
9
Aminoglycosides: activity and resistance.
Antimicrob Agents Chemother. 1999 Apr;43(4):727-37. doi: 10.1128/AAC.43.4.727.
10
The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.
Clin Infect Dis. 1997 Jan;24 Suppl 1:S46-62. doi: 10.1093/clinids/24.supplement_1.s46.
Zotero 插件